Next Article in Journal
Pentacoordinated Chloro-Iron(III) Complexes with Unsymmetrically Substituted N2O2 Quadridentate Schiff-Base Ligands: Syntheses, Structures, Magnetic and Redox Properties
Previous Article in Journal
Modification of TiO2 Surface by Disilanylene Polymers and Application to Dye-Sensitized Solar Cells
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessArticle
Inorganics 2018, 6(1), 4; https://doi.org/10.3390/inorganics6010004

Pt(IV)/Re(I) Chitosan Conjugates as a Flexible Platform for the Transport of Therapeutic and/or Diagnostic Anticancer Agents

1
Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy
2
Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Estrada Nacional 10 (km 139,7), 2695-066 Bobadela LRS, Portugal
*
Authors to whom correspondence should be addressed.
Received: 9 November 2017 / Revised: 15 December 2017 / Accepted: 21 December 2017 / Published: 27 December 2017
(This article belongs to the Special Issue Metal Complexes for Imaging and Therapy)
Full-Text   |   PDF [1644 KB, uploaded 27 December 2017]   |  

Abstract

New chitosan derivatives modified with (3-carboxypropyl)trimethylammonium chloride (1) and coupled with (OC-6-44)-diammine(4-carboxypropanoato)dichloridoethanolatoplatinum(IV) (2), were synthesized and their preliminary biological evaluation carried out in human tumor cells. Some of these derivatives were also loaded with a chelating ligand (3) that was derived from bis(quinolin-2-ylmethyl)amine to obtain chitosan-based nanoparticles for an EPR-mediated delivery of Pt(IV) prodrugs and Re(I) tricarbonyl complexes (4), to explore a multimodal theranostic approach to cancer. The cytotoxicity of the different chitosan conjugates (C12, C123, and C1234), carrying different combinations of the Pt(IV) complex, the chelator and the Re(I) complex, was evaluated in the A2780 human ovarian cancer cell line using the MTT assay. The Pt(IV)-containing nanosystems showed low to moderate cytotoxic activity (IC50 values in the range 13.5–33.7 µM) and was comparable to that found for the free Pt(IV) complex (IC50 = 13.7 µM). Therefore, the Pt(IV)-chitosan conjugation did not enhance the cytotoxic activity of the Pt(IV) prodrug, which certainly reflects the inefficient cellular uptake of the nanoconjugates. Nevertheless, a clearer view of their potential for the delivery of anticancer agents requires further in vivo tests because the EPR effect increases extravasation and retention within the tumor tissue, not necessarily within the tumor cells. View Full-Text
Keywords: theranostics; platinum prodrugs; rhenium complexes; chitosan; drug targeting and delivery theranostics; platinum prodrugs; rhenium complexes; chitosan; drug targeting and delivery
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Gabano, E.; do Quental, L.; Perin, E.; Silva, F.; Raposinho, P.; Paulo, A.; Ravera, M. Pt(IV)/Re(I) Chitosan Conjugates as a Flexible Platform for the Transport of Therapeutic and/or Diagnostic Anticancer Agents. Inorganics 2018, 6, 4.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Inorganics EISSN 2304-6740 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top